Louis P. Garrison

Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer

D. Lubeck, E. Perez, L. Garrison, 2007, Cancer.

Health technology assessment in low‐ and middle‐income countries: a landscape assessment

Andy Stergachis, L. Garrison, A. Stergachis, 2016 .

Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status

Bruce Wang, E. Perez, L. Garrison, 2013, Cancer.